PRIMARY STUDY
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Key Findings: Resulting data showed that BCP was protecting the test animals against seizure activities as well as several comorbidities.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Spain
Year of Pub: 2021
Cannabinoids Studied:
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Citation: Alonso C, et al. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome. Neuropharmacology. 2022; 205:108914. doi: 10.1016/j.neuropharm.2021.108914
Authors: Alonso C, Satta V, Díez-Gutiérrez P, Fernández-Ruiz J, Sagredo O
